当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Viren Morris
Parkinson’s disease (PD) is a complex neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra region of the brain. This degeneration leads to a range of motor and non-motor symptoms, including tremors, bradykinesia, rigidity, and cognitive impairment. Despite extensive research, the precise etiology of PD remains elusive, involving a combination of genetic and environmental factors. This comprehensive review aims to elucidate the current understanding of the molecular and cellular mechanisms underlying PD pathology, exploring the interplay between genetic mutations, mitochondrial dysfunction, oxidative stress, and inflammation. Accurate diagnosis of PD remains challenging, particularly in the early stages when symptoms may be subtle. We discuss the evolving landscape of diagnostic tools, from clinical assessments to advanced neuroimaging techniques and biomarker discovery. Early and accurate diagnosis is crucial for implementing timely interventions and personalized treatment strategies. The review also addresses the role of emerging technologies, such as artificial intelligence and machine learning, in refining diagnostic precision and predicting disease progression. The treatment landscape for PD has witnessed significant advancements, ranging from traditional pharmacotherapies to innovative neuroprotective and regenerative approaches. Levodopa, the gold standard in PD pharmacotherapy, is discussed in conjunction with adjunct therapies and deep brain stimulation. Additionally, we highlight promising experimental treatments, including gene therapies, stem cell transplantation, and targeted neuroprotective agents, shedding light on their potential to modify disease progression and enhance patient outcomes. The impact of PD extends beyond motor symptoms, encompassing a spectrum of non-motor manifestations that significantly affect patients’ quality of life. This review examines the diverse array of non-motor symptoms, including autonomic dysfunction, sleep disturbances, and psychiatric complications. A comprehensive understanding of these aspects is crucial for holistic patient management and the development of targeted interventions.